– UK, Oxford – Oxford Biomedica plc (LON: OXB), a quality and innovation-led cell and gene therapy CDMO, today announced the appointment of Peter Soelkner to its Board as a Non-Executive Director, effective from 15 March 2024.
“We are delighted to welcome Peter Soelkner given his impressive track record in significantly growing Vetter, a leading global CDMO from $200m to more than $1bn in revenues,” said Board Chairman, Dr. Roch Doliveux.
Concurrently, the Company also announced that Catherine Moukheibir and Dr. Michael Hayden will not stand for re-election at the upcoming AGM in June 2024.
About Peter Soelkner
Peter Soelkner has more than 30 years of experience in the global pharmaceutical services industry with significant CDMO expertise. He is currently Managing Director of Vetter Pharma, a global Aseptic Filling and Packaging CDMO, where over the past 15 years he has helped grow revenues from $200 million to more than $1 billion. Before Vetter, Peter Soelkner held various senior positions at Sartorius including VP of the Americas region where he expanded the global footprint of the business across the US and multiple sectors.
Peter Soelkner said: “I am pleased to be joining this innovative, client-centric, global business at such an exciting juncture in the Company’s journey. In my view Oxford Biomedica is extremely well-positioned as a pure-play CDMO and I am excited to apply my skillset and experience to help deliver the strategy to clients, enabling them to deliver life-changing therapies to patients.”
Peter Soelkner has an MBA from Columbia Business School, New York, and a Masters in Chemical Engineering from TU Dortmund University, Germany.
About Oxford Biomedica
Oxford Biomedica is a quality and innovation-led cell and gene therapy contract development and manufacturing organization with a mission to enable its clients to deliver life-changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialization. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.
SOURCE: https://oxb.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.